BioElectronics Corporation (OTC: BIEL) announced today the commercial launch of ActiPatch in Taiwan through its distributor, Aphrodite Medical Group. This expansion marks a significant step in bringing drug-free, non-invasive pain therapy to a new market, challenging traditional pain management approaches that rely heavily on pharmaceuticals.
ActiPatch is a US FDA-cleared medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and can be worn during sleep, offering a practical alternative to medications for conditions such as musculoskeletal pain. The device's drug-free nature addresses growing concerns about opioid addiction and side effects from long-term painkiller use.
Kelly Whelan, CEO of BioElectronics Corporation, emphasized the strategic importance of the partnership: "The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch® in Taiwan. Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way." The initial shipment of units has been completed, positioning ActiPatch for a coordinated market launch in Q2 2026.
Aphrodite Medical Group, a well-established healthcare provider in Taiwan, will lead market introduction, physician engagement, and patient access initiatives. Yang Pei-Hsien, Vice President of Aphrodite Medical Group, stated, "We are pleased to bring ActiPatch® to Taiwan as part of our commitment to delivering innovative, patient-centered therapies. This technology aligns with the growing demand for safe, effective, and drug-free pain management options."
The launch reinforces BioElectronics' strategy to expand through high-quality distribution partnerships in key markets while focusing on clinically validated, scalable bioelectronic therapies. As reported on NewMediaWire, the rollout will initially target musculoskeletal pain management, with opportunities for expansion into additional clinical applications over time.
This move into Taiwan is particularly important given the region's healthcare landscape. Taiwan has a rapidly aging population and high prevalence of chronic pain conditions, yet traditional treatments often involve medications with significant side effects. ActiPatch offers a non-pharmacological option that could reduce reliance on opioids and NSAIDs, aligning with global trends toward safer pain management.
BioElectronics Corporation (OTC: BIEL) continues to advance its portfolio of bioelectronic therapies, including RecoveryRx®, which also uses pulsed shortwave technology. The company's FDA-cleared devices represent a growing category of electroceuticals that modulate nerve activity to treat pain without drugs.
The implications of this launch extend beyond Taiwan's borders. As BioElectronics demonstrates successful market entry through partnerships like Aphrodite Medical Group, it paves the way for future expansions into other Asian markets. The drug-free pain management sector is expected to grow significantly as patients and healthcare providers seek alternatives to opioids, making this announcement a bellwether for broader adoption of bioelectronic therapies.
